[177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.doi:10.1200/JCO.2022.40.16_suppl.5001115001#Background:In the phase 3 VISION trial, targeted radioligand therapy with lutetium (177Lu) vipivot...
2e17058#Background:The phase III VISION trial demonstrated that177Lu-PSMA-617 (PSMA-RLT) prolonged overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). Common side effects of PSMA-RLT include xerostomia, bone pain, and myelosuppression. The objective of this ...
In this randomized trial in men with mCRPC, we aim to determine the efficacy of a response-based flexible dosing schedule of177Lu-PSMA-617 RLT administered up to 12 treatment cycles compared to the current standard of care.Methods:This is an investigator-initiated prospective phase 2, open-...